BioArctic's partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease
Stockholm, January 7, 2023 - BioArctic ABs partner Eisai announced today they have submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration supporting the... | January 7, 2023
Uppsala Lan Oskar Bosson Gunilla Osswald Uppsala University Vp Communications National Institutes Of Health
Source: marketscreener.com